Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, community ranking, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Does the media refer more to GMAB or TAK?

In the previous week, Genmab A/S had 6 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 10 mentions for Genmab A/S and 4 mentions for Takeda Pharmaceutical. Genmab A/S's average media sentiment score of 0.96 beat Takeda Pharmaceutical's score of 0.64 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 23.49% compared to Takeda Pharmaceutical's net margin of 6.49%. Genmab A/S's return on equity of 14.64% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	23.49%	14.64%	12.37%
Takeda Pharmaceutical	6.49%	10.00%	4.78%

Does the MarketBeat Community favor GMAB or TAK?

Genmab A/S received 60 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 62.75% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 160 62.75%	Underperform Votes 95 37.25%
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%

Which has higher valuation and earnings, GMAB or TAK?

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$19.84B	0.69	$631.91M	$1.03	19.99
Takeda Pharmaceutical	$28.20B	1.54	$994.06M	$0.58	23.48

Do analysts prefer GMAB or TAK?

Genmab A/S currently has a consensus price target of $45.20, suggesting a potential upside of 119.52%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals and insiders believe in GMAB or TAK?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has more risk and volatility, GMAB or TAK?

Genmab A/S has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Summary

Genmab A/S beats Takeda Pharmaceutical on 13 of the 18 factors compared between the two stocks.